Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inovio Pharmaceuticals, Inc. - Common Stock (NQ:INO)

2.500 +0.150 (+6.38%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Inovio Pharmaceuticals, Inc. - Common Stock

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
From AVACTA GROUP PLC
Via GlobeNewswire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
From Inovio Pharmaceuticals, Inc.
Via GlobeNewswire
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Two Appealing Biotech Stocks for Two Distinct investors
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles 
Via MarketBeat
Topics Intellectual Property
Does Amarin Deserve a Spot in Your Portfolio after Earnings ?
Amarin recently announced its earnings for Q2'22 with mixed results. Here we'll examine the pros and cons of having this penny stock in your portfolio. 
Via MarketBeat
Topics Earnings
Rising Test Accuracy Standards Needed as On-Site Demand for Covid-19 Testing Increases
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – After the launch of US President Joe Biden’s pushing of mandatory vaccination/testing in the... 
Via FinancialNewsMedia
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 6, 2021 – USA News Group – As vaccine passport programs continue to roll out in new markets across the globe, especially in... 
Via FinancialNewsMedia
Growing Acceptance Of Digital Health Services is a Huge Boon for Healthcare Cloud Computing Market
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Cloud computing increases real-time data collection and improves accessibility to the data. It has outpaced the conventional... 
Via FinancialNewsMedia
INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO
From Kahn Swick & Foti, LLC
Via Business Wire
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
Palm Beach, FL – October 20, 2021 – FinancialNewsMedia.com News Commentary – Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing... 
Via FinancialNewsMedia
As the Virus Continues, the Global Covid-19 Vaccine Market Expected to Reach $25 Billion By 2024
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.